Cancer Science & Therapy

Ingrid HG Østensen

Publications

• Research Article
  Characterization of Treatment Response to Recombinant Interferon-a2b in Osteosarcoma Xenografts
  Author(s): Christoph R Müller, Heidi M Namløs, Johan Bjerner, Ingrid HG Østensen, Gunnar Sæter, Sigbjørn Smeland, Øyvind S Bruland and Ola MyklebostChristoph R Müller, Heidi M Namløs, Johan Bjerner, Ingrid HG Østensen, Gunnar Sæter, Sigbjørn Smeland, Øyvind S Bruland and Ola Myklebost
  
  Interferons (IFNs) may target cancer cells both through their regulation of the immune response, effect on angiogenesis and through direct effect on cancer cells. Treatment response has been demonstrated in osteosarcoma patients, but tumour resistance to IFN-a is common. Hence, understanding the molecular mechanisms involved in response and resistance is essential for improving therapeutic efficacy. Of five xenografts screened for specific growth delay in response to treatment with unconjugated and PEGylated IFN-a2b, one displayed growth inhibition and tumour shrinkage. Growth inhibition increased on a dosing schedule of PEGylated IFN every third day. Xenografts resistant to PEGylated IFN were similarly resistant to unconjugated IFN. Combination treatment with IFN-a2b and doxorubicin resulted in improved growth control rates. Transcriptional profiling analysis of the one sensitive and.. Read More»
  

  Abstract PDF